

BioSciCon, Inc.

Biomedical Science Consulting, Inc.




BioSciCon, Inc.
14905 Forest Landing Circle
Rockville, MD 20850-3924
Tel: 301-610-9130
Fax: 301-610-7662
E-mail: info@bioscicon.com
Web Site: www.bioscicon.com

BioSciCon, Inc., The Biomedical Science Consulting Company is women-owned biotechnology R&D organization incorporated in 1996 with primary focus on the development of a proprietary platform MarkPap® technology for improvement of cytological early detection of cervical cancer and making it affordable, accessible and available world-wide. The other three entities of the **Consortium** are **MarkPap LLC**, **MarkPap Pacific LLC** and **MarkPap India LLC** for commercialization of MarkPap® products as they emerge from R&D phase (www.bioscicon.com). **The Global Academy for Women's Health, Inc.** is an independent non-profit organization with a mission to promote excellence in women's health science and education, which integrates prior and current non-profit activities of BioSciCon founders continuing their legacy to work for public benefit (www.markpap.com).



Olivera Markovic, MD, PhD
Professor and founding Director

BioSciCon designs and develops patented biomarker-based MarkPap® platform technology products and services. Biomarker is exclusively present in abnormal cervical cells. When visualized with MarkPap test, it appears as a red pigment flagging abnormal cells not to be missed even by a low-trained person. Detecting abnormal cells on time makes a difference between life and death, since cervical cancer is a preventable disease if detected on time, but deadly if allowed to develop. The first generation MarkPap® products are **MarkPap® Reagent Kit** with accessories (*MarkPap Solution*, *COMBO Control Slides*) for manual and automated slide processing (*MarkPap® Auto*). The second generation is **MarkPap® Telecytology Service** (*MarkPap® Digital* - for digital and *MarkPap® Wireless* - for wireless) transmission of images from the point-of-care to distant centers for expert diagnosis. The third generation is represented with **MarkPap® Self**, the specimen's self-collecting Kit. The new biomarker MEDYCO recently evolved as a powerful tool combining metabolic, morphological and prognostics feature of suspicious cells.



The biomarker is not only contributing to the test to be more accurate, faster, less expensive and more affordable for women, but its presence allows the low-trained person at the point-of-care to recognize abnormal cells and transmit their images for distant reading (telecytology). The MarkPap® Self provides screening benefit to women who do not have access to medical institutions or those who avoid visiting gynecologist. MarkPap® Wireless is to allow the images to be captured and transmitted with cell phone from anywhere in the world. Currently, there are about 520,000 new cases of cervical cancer diagnosed each year globally and 260,000 women die from a preventable disease in the 21st Century. Less than 10% women at average participate in cervical cancer screening. MarkPap technology can make a difference.

MarkPap® products are available for licensing and sales under local regulations.

BIOSCICON COMPANY INFORMATION

Founded: 1996

Website:
www.bioscicon.com

Industry: Healthcare

Stage: Commercialization

Business model:

Incorporating trade companies for promotion and sale of MarkPap® PlatformTechnology products and services in selected world areas meeting local specificity of needs and demands

Products & Services:

- Diagnostic kits
- Self-sampling specimen collection kit
- Telecytopathology service
- IT networking maintenance - connection with ITTHC
- Customer Service

Patents, Copyrights and Trademark


- Parent patent CAP-PAP Test Kit of 2000. Will be replaced with 2018 MarkPap® Platform Technology products and services.
- Copyrights - US library of Congress
- Trade name: MARKPAP

Investment sought:

- Additional patent applications: \$100,000
- Approval to market and distribute: \$500,000
- Working Capital: Average \$500,000 per market selection
- Investment to-date: 10 million
- Total amount of financing sought: 2 million initially

Founders:

1. Olivera Markovic, MD, PhD
2. Nenad Markovic, MD, PhD



2nd ed. 2016, XLI, 527 p. 466 illus., 281 illus. in color.

 **Printed book**


Hardcover

- ▶ 154,99 € | £115.50 | \$189.00
- ▶ *165,84 € (D) | 170,49 € (A) | CHF 170.50

 **eBook**

Available from your library or

- ▶ springer.com/shop

 **MyCopy**

Printed eBook for just

- ▶ € | \$ 24.99
- ▶ springer.com/mycopy

